SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin-converting enzyme 2 (ACE2) receptors. Blocking this interaction with inhibitors could prevent ...

The key player in SARS-CoV-2's infection process is the receptor binding domain (RBD) of the spike protein. The RBD determines how well the virus binds to ACE2, the human cellular receptor ...

The new virus, too, was discovered in the bats first..New coronavirus variant , China New Coronavirus , HKU5 COV-2 ...

Identification of HKU5-CoV-2 (a member of the HKU5 lineage 2), a new merbecovirus found in bats of Zhejiang, Anhui, and ...

After Covid-19 and HMPV, a new bat coronavirus discovered in China has sparked concerns among health officials and has triggered another pandemic fear. The newly discovered virus, however, is yet to ...

Shaibani, A. , Maallah, M. and Maallah, A. (2025) Antiviral Activity of Natural Compounds Immuno Formula Shiban2/5 against ...

It's been five years since COVID-19 was declared a global pandemic. As SARS-CoV-2 shifts to endemic status, questions about its future evolution remain.

The COVID-19 pandemic highlighted the urgent need for effective therapeutic agents against SARS-CoV-2. Although vaccines ...

1, KP.3.1.1, XEC, and LP.8.1. PEMGARDA targets the SARS-CoV-2 spike protein receptor binding domain (RBD), thereby inhibiting virus attachment to the human ACE2 receptor on host cells.

Small-molecule inhibitors targeting viral proteins could serve as an effective alternative for controlling the spread of COVID-19 at both individual and community levels. In this vein, a recent study ...